ライフサイエンスコーパス: nitroglycerin

1 a nitric oxide synthase-independent agonist (nitroglycerin).

2 tal mortality was similar for nesiritide and nitroglycerin.

3 tanding of the clinical impact of angina and nitroglycerin.

4 s of the initial dose of sublingual or spray nitroglycerin.

5 , 35% (49 of 141) had chest pain relief with nitroglycerin.

6 in ointment, and intraarterial verapamil and nitroglycerin.

7 d administration of 200 microg intracoronary nitroglycerin.

8 g intracoronary adenosine, acetylcholine and nitroglycerin.

9 There were no differences in response to nitroglycerin.

10 -guanosine monophosphate (8-bromo-cGMP), and nitroglycerin.

11 tery relaxation to nitroprusside, but not to nitroglycerin.

12 intracoronary infusions of acetylcholine and nitroglycerin.

13 No therapy improved the dilator response to nitroglycerin.

14 intracoronary but not with intrapericardial nitroglycerin.

15 n of the endothelium-independent vasodilator nitroglycerin.

16 measured after administration of sublingual nitroglycerin.

17 dministration of 200 microg of intracoronary nitroglycerin.

18 s examined using intracoronary adenosine and nitroglycerin.

19 fter the administration of 0.4 mg sublingual nitroglycerin.

20 ium-independent relaxation was studied using nitroglycerin.

21 of endothelial independent vasodilation with nitroglycerin.

22 ct rabbit aorta and increased sensitivity to nitroglycerin.

23 amined by use of intracoronary adenosine and nitroglycerin.

24 nges in systemic hemodynamics were seen with nitroglycerin.

25 d by the endothelium-independent vasodilator nitroglycerin.

26 l segments, with trends toward reversal with nitroglycerin.

27 Topical application of nitroglycerin (0.1 and 1.0 microM) produced similar dose

28 at rest and during intracoronary infusion of nitroglycerin (0.3 to 0.6 microg.kg(-1).min(-1)).

29 bjects received repeated doses of sublingual nitroglycerin (0.4 mg) after the last dose of placebo or

30 0.3 or 0.5 microgram.kg-1.min-1 intravenous nitroglycerin; 0.0125, 0.025, or 0.1 mg clonidine orally

31 l-penicillamine (10(-4) mol/L, -34+/-5%) and nitroglycerin (10(-4) mol/L, -21+/-5%), also decreased t

32 arterial norepinephrine (1.2 micrograms) and nitroglycerin (100 micrograms).

33 oline (10(-8), 10(-7), and 10(-6) mol/L) and nitroglycerin (15 microg/min).

34 nitroso-N-acetyl-penicillamine (-35+/-7%) or nitroglycerin (-16+/-5%) was not significantly affected

35 Intrapericardial nitroglycerin (200 microg) was administered in five York

36 ylcholine (54 microgram over 2 minutes), and nitroglycerin (200 microgram) into the left anterior des

37 o BQ-123 with that elicited by intracoronary nitroglycerin (200 microgram).

38 However, neither the dilator response to nitroglycerin (21 +/- 14% vs. 18 +/- 13%) nor the baseli

39 ylcholine was -1% (range -33% to 28%) and to nitroglycerin 22% (range 0% to 54%).

40 /-5% in both groups) and exogenous NO donor, nitroglycerin (-33+/-7% vs. -30+/-3%).

41 enosine (100 microgram. kg(-1). min(-1)) and nitroglycerin (40 microgram/min).

42 (29 g over 2 days) with background low-dose nitroglycerin (7.2 mg over 2 days) on early cardiac magn

43 es from the CEE group dilated in response to nitroglycerin (9.1+/-2.1%, P<.05 versus control), wherea

44 activation as a fundamental requirement for nitroglycerin action at pharmacologically relevant conce

45 rasonography) were measured before and after nitroglycerin administration (400 mug s/l).

46 MBF in the ischemic microcirculation during nitroglycerin administration occurs in tandem with incre

47 Patients continued to exercise after nitroglycerin administration with less ST-segment depres

48 es after either placebo or 0.8 mg sublingual nitroglycerin administration, followed by repeat SPECT i

49 ne whether calcium antagonist, compared with nitroglycerin, administration attenuates left ventricula

50 enosine diphosphate (ADP)) and -independent (nitroglycerin) agonists before and during application of

51 pendent (NMDA and kainate) and -independent (nitroglycerin) agonists in nondiabetic and diabetic rats

52 e therapies improved the dilator response to nitroglycerin (all P>/=0.184).

53 Nitroglycerin also evoked greater mean maximal decreases

54 Vasodilation to nitroglycerin also increased, but this effect did not re

55 the presence of inducible ischemia or use of nitroglycerin, although they were younger and more likel

56 ion), and after sublingual administration of nitroglycerin (an endothelium-independent vasodilator).

57 ugh these vessels showed normal responses to nitroglycerin, an endothelium-independent vasodilator.

58 Nitroglycerin, an exogenous nitric oxide donor, caused a

59 een the magnitude of the dilator response to nitroglycerin and acetylcholine.

60 ficant coronary stenoses, those who received nitroglycerin and had coronary collateral circulation we

61 CAdiam) during a cold pressor test and after nitroglycerin and IMT were measured with ultrasound in 9

62 intracoronary acetylcholine, adenosine, and nitroglycerin and intracoronary ultrasound at the time o

63 poxic vasodilation and to the bioactivity of nitroglycerin and mediates the cardiovascular protective

64 nd endothelium-independent vasodilation with nitroglycerin and sodium nitroprusside were studied befo

65 perties that also potentiates the effects of nitroglycerin and thus represents a potentially benefici

66 bilized by balloon tamponade and vasopressin/nitroglycerin and TIPS placed semiurgently within 12 hou

67 HS was not triggered by nitroglycerin and was unaffected by sumatriptan, dihydro

68 inistration of acetylcholine, adenosine, and nitroglycerin and were then followed up for clinical out

69 ve carbon regions to the target contaminant (nitroglycerin) and degradation by sulfur-based intermedi

70 act readily with glycerin trinitrate (GTN ) (nitroglycerin) and propylene dinitrate, with rate consta

71 vers, including postural changes, sublingual nitroglycerin, and bicycle exercise, demonstrated expect

72 namics and symptoms at 3 hours compared with nitroglycerin, and has been added to the therapeutic arm

73 , wild-type controls stopped vasodilating to nitroglycerin, and the vascular sensitivity to nitroglyc

74 by the most commonly used antianginal drug, nitroglycerin, are incompletely understood.

75 The physiological effects of nitroglycerin as a potent vasodilator have long been doc

76 Nitroglycerin as needed and a beta- or calcium-channel b

77 ylcholine, the calcium ionophore A23187, and nitroglycerin, as well as superoxide production and NO s

78 In response to nitroglycerin at 4, 8, and 24 h, standing systolic BP fe

79 0.05), with no difference in the response to nitroglycerin at 48, 72, and 96 h (p > 0.2).

80 Sublingual nifedipine but not nitroglycerin attenuates this process and suggests that

81 s mainly considered to be an alternative for nitroglycerin, because it has fewer side-effects, and it

82 in implants in response to acetylcholine and nitroglycerin before and following topical application o

83 lar effect, cardiomyocytes were treated with nitroglycerin before H-R.

84 a nitric oxide synthase-independent agonist (nitroglycerin) before and during application of superoxi

85 consisting of aspirin, intravenous heparin, nitroglycerin, beta-blockers, and analgesics.

86 eased by infusion of diethylamine/NONOate or nitroglycerin but was unaffected by Angeli's salt.

87 muscle cells or isolated blood vessels with nitroglycerin caused PKG1alpha disulfide dimerization.

88 Administration of nitroglycerin causes changes in the systemic and coronar

89 ntively deficient in hypotensive response to nitroglycerin compared with wild-type littermates as mea

90 vs. 3.31 +/- 0.22 on placebo; p = 0.028) and nitroglycerin consumption (2.03 +/- 0.20 on ranolazine v

91 versus 3.5+/-1.2 episodes/week) and reduced nitroglycerin consumption (33.8+/-2.3 versus 4.1+/-1.5 t

92 cy averaged 5.63 +/- 0.18 episodes/week, and nitroglycerin consumption averaged 4.72 +/- 0.21 tablets

93 ignificantly reduced frequency of angina and nitroglycerin consumption compared with placebo and was

94 Efficacy was also assessed by nitroglycerin consumption per week and the Seattle Angin

95 ercept or attenuation of liver ischemia with nitroglycerin did not decrease this hepatic stellate cel

96 Responses to adenosine and nitroglycerin did not differ significantly.

97 dothelium-independent dilatation (sublingual nitroglycerin) did not differ among the groups at baseli

98 lium-independent dilatation (EID; sublingual nitroglycerin) did not differ between groups.

99 S, 100 U/mL of heparin, and 250 microg/mL of nitroglycerin eliminated infusion-related infarction.

100 ium-dependent dilation) and after sublingual nitroglycerin (endothelium-independent dilation).

101 um-dependent vasodilation) and to sublingual nitroglycerin (endothelium-independent vasodilation).

102 Nitroglycerin-enhanced coronary MRA can noninvasively me

103 bute to the powerful antiischemic effects of nitroglycerin, especially during low-flow states.

104 Compared with the dilation from nitroglycerin, ET-1 contributed to 39% of the coronary t

105 However, the molecular mechanisms by which nitroglycerin exerts its biological functions are still

106 Sublingual nitroglycerin, given to five subjects with angina while

107 n of 1,2-glyceryl dinitrate and nitrite from nitroglycerin (glyceryl trinitrate [GTN]) within mitocho

108 ity of the cellular mechanisms through which nitroglycerin (glyceryl trinitrate, GTN) elicits nitric

109 ase-2 (ALDH2) catalyzes the bioactivation of nitroglycerin (glyceryl trinitrate, GTN) in blood vessel

110 Nitroglycerin (glyceryl trinitrate, GTN), originally man

111 e headache 4-6 h after infusing the NO donor nitroglycerin [glyceryl trinitrate (GTN)] to migraineurs

112 sGC was only activated 67-fold by nitroglycerin (GTN) and Cys; and in the absence of Cys,

113 Nitrates such as nitroglycerin (GTN) and nitric oxide donors such as S-ni

114 ltured porcine aortic endothelial cells with nitroglycerin (GTN) or 1H-[1,2,4]-oxadiazolo[4,3-a]quino

115 scular bioactivation of the antianginal drug nitroglycerin (GTN) to yield nitric oxide (NO) or a rela

116 scular bioactivation of the antianginal drug nitroglycerin (GTN), resulting in activation of soluble

117 iethylamine/NONOate nor the nitrovasodilator nitroglycerin had an appreciable effect on basal levels.

118 Although nitroglycerin has remained in clinical use since 1879, t

119 interval [CI], 1.25-2.38), particularly oral nitroglycerin (HR, 1.81; 95% CI, 1.14-2.90), was associa

120 When given concomitantly with nitroglycerin, hydralazine completely prevented the deve

121 We hypothesized that nitroglycerin improves O2 delivery to ischemic tissue by

122 not alter responses of the basilar artery to nitroglycerin in alcohol-fed rats, and did not alter res

123 ge in the E/A' ratio after administration of nitroglycerin in patients with a high versus a normal pr

124 The use of nitroglycerin in the treatment of angina pectoris began

125 he release of NO from nitroprusside, but not nitroglycerin, in calf pulmonary artery.

126 Nitroglycerin, in the absence of supplemental ascorbate,

127 Clonidine and nitroglycerin increased gastric compliance, but normal p

128 The belief that chest pain relief with nitroglycerin indicates the presence of active coronary

129 BF, as an index of synaptic activity, during nitroglycerin-induced cluster headache attacks in nine p

130 iated dilatation (endothelium dependent) and nitroglycerin-induced dilatation (endothelium independen

131 steine were measured at each time point, and nitroglycerin-induced dilatation at was assessed at 0, 1

132 Nitroglycerin-induced dilatation was unchanged after bot

133 Nitroglycerin-induced dilatation was unchanged by oral h

134 ed dilation (FMD; endothelium dependent) and nitroglycerin-induced dilation (NID; endothelium indepen

135 ion had no effect on endothelium-independent nitroglycerin-induced dilation.

136 7 +/- 1.6%, p < 0.02), with no difference in nitroglycerin-induced endothelium-independent vasodilata

137 kedly blunted in TG mice in response to both nitroglycerin-induced hypotension and phenylephrine-indu

138 The nitroglycerin-induced increase in tissue Po2 was disprop

139 In contrast, no significant difference in nitroglycerin-induced vascular relaxation as well as nor

140 om knock-ins were markedly less sensitive to nitroglycerin-induced vasodilation (EC(50)=39.2 +/- 10.7

141 establish whether kinase oxidation underlies nitroglycerin-induced vasodilation in vivo, we used a Cy

142 We hypothesized that nitroglycerin-induced vasodilation is mediated by disulf

143 Clinical Dementia Rating scores) and FMD and nitroglycerin-induced vasodilation of the brachial arter

144 lfide formation is a significant mediator of nitroglycerin-induced vasodilation, and tolerance to nit

145 rce of NO responsible for low-dose (1-10 nM) nitroglycerin-induced vasorelaxation.

146 Flow-mediated, endothelium-dependent and nitroglycerin-induced, endothelium-independent vasodilat

147 With background nitroglycerin infusion administered to all patients, tho

148 oline infusion) and endothelium-independent (nitroglycerin infusion) vasodilation of the radial arter

149 nistration of milrinone, norepinephrine, and nitroglycerin infusions.

150 ary diameter measurement after intracoronary nitroglycerin injection 5, 20, and 35 mm distal to the s

151 dothelium-dependent cases; and intracoronary nitroglycerin injection for endothelium-independent case

152 Bypass time, intravenous nitroglycerin injections, or myocardial infarction in th

153 Nitroglycerin is a nitric oxide donor that exerts potent

154 cerin-induced vasodilation, and tolerance to nitroglycerin is associated with loss of kinase oxidatio

155 s NAC administered with low-dose intravenous nitroglycerin is associated with reduced infarct size in

156 gastrointestinal tract, and the skin; thus, nitroglycerin is available in a number of preparations f

157 The coronary vasodilator response to nitroglycerin is not significantly enhanced in patients

158 interaction between tadalafil and sublingual nitroglycerin lasted 24 h, but was not seen at 48 h and

159 Isosorbide dinitrate and nitroglycerin markedly inhibited KCl contractions (47 +/

160 brachial artery diameter (flow mediated and nitroglycerin mediated), with the particulate pollutant

161 mediated (-10.7%; 95% CI, -17.3 to -3.5) and nitroglycerin-mediated (-5.4%; 95% CI, -10.5 to -0.1) va

162 dilatation (FMD) and endothelial-independent nitroglycerin-mediated dilatation (NMD).

163 ial stiffness, flow-mediated dilation (FMD), nitroglycerin-mediated dilation (GMD), urinary nitric ox

164 tests (VFTs): flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD), carotid-femoral p

165 ediated dilation (FMD)] and before and after nitroglycerin-mediated dilation (NMD).

166 vity, we examined flow-mediated dilation and nitroglycerin-mediated dilation in 73 healthy subjects (

167 e no differences in median flow-mediated and nitroglycerin-mediated dilation or CPT of the brachial a

168 Nitroglycerin-mediated dilation was also significantly l

169 d brachial artery flow-mediated dilation and nitroglycerin-mediated dilation were determined by ultra

170 hial artery flow-mediated dilation (FMD) and nitroglycerin-mediated dilation were determined in women

171 21.7 to -2.4), and PM2.5 was associated with nitroglycerin-mediated reactivity (-7.6%; 95% CI, -12.8

172 Flow- and nitroglycerin-mediated reactivity of the brachial artery

173 At baseline, nitroglycerin-mediated vasodilation also was impaired (1

174 No differences were found in nitroglycerin-mediated vasodilation and in vitro ET-1 pr

175 y, flow-mediated, endothelium-dependent, and nitroglycerin-mediated, endothelium-independent vasodila

176 d efficacy of a novel formulation of topical nitroglycerin, MQX-503, in the treatment of RP in an amb

177 reinjection in 80% of patients who received nitroglycerin (n = 20) compared with 40% of the patients

178 the Valsalva maneuver (n = 27) or sublingual nitroglycerin (n = 36), or both (n = 14).

179 Cases in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were

180 Nitroglycerin (NG) and nitrocellulose (NC) are constitue

181 1,3,5-trimethylene-2,4,6-trinitramine (RDX), nitroglycerin (NG) and pentaerythritol tetranitrate (PET

182 species of Pseudomonas capable of utilizing nitroglycerin (NG) as a sole nitrogen source were isolat

183 P. fluorescens I-C that removed nitrite from nitroglycerin (NG) by cleavage of the nitroester bond we

184 An IMS spectrum of nitroglycerin (NG) was obtained utilizing RIIN for trand

185 uene (2,6-DNT), 2,4,6-trinitrotoluene (TNT), nitroglycerin (NG), 1,3,5-trinitroperhydro-1,3,5-triazin

186 ith diuretics, intravenous vasodilators (ie, nitroglycerin, nitroprusside), and intravenous inotropes

187 ol) or treated by direct LAD infusion of (i) nitroglycerin (NTG) (0.5 microg.kg(-1).min(-1)); (ii) 8-

188 of continuous transdermal administration of nitroglycerin (NTG) (10 mg/24 hours) on platelet free ra

189 1.3 vs. 2.4%, p = 0.014) and vasodilation to nitroglycerin (NTG) (13.0 vs. 17.8%, p < 0.05) were sign

190 This study was conducted to compare nitroglycerin (NTG) 0.4% ointment with placebo for pain

191 Intracoronary nitroglycerin (NTG) administered to five dogs revealed a

192 ects of high-dose (50 to 100 mg) transdermal nitroglycerin (NTG) and placebo given daily for 12 hours

193 nd endothelium-independent vasodilation with nitroglycerin (NTG) and sodium nitroprusside (SNP) befor

194 The efficacy of nitroglycerin (NTG) as a vasodilator is limited by toler

195 e antiarrhythmic effects of intrapericardial nitroglycerin (NTG) during acute myocardial ischemia in

196 A 60-minute intravenous (IV) infusion of nitroglycerin (NTG) ending 1 hour before occlusion reduc

197 Nitroglycerin (NTG) improves myocardial perfusion, reduc

198 Nitroglycerin (NTG) induces delayed preconditioning (PC)

199 dralazine (HYD) alone or in combination with nitroglycerin (NTG) or isosorbide dinitrate restores Ca(

200 to receive a 4-hour intravenous infusion of nitroglycerin (NTG) or normal saline; on the following d

201 -month) efficacy of intermittent transdermal nitroglycerin (NTG) patches on LV remodeling in 291 surv

202 We have previously shown that nitroglycerin (NTG) therapy increases vascular expressio

203 d the hypothesis that chronic treatment with nitroglycerin (NTG) to induce nitrate tolerance, which i

204 Ten healthy male subjects received nitroglycerin (NTG) transdermally at a dosage of 0.4 mg/

205 esponse to sublingual (SL) administration of nitroglycerin (NTG) was evaluated at baseline and at 2 a

206 he brachial artery to flow and to sublingual nitroglycerin (NTG) was recorded (conduit vessel respons

207 Nitroglycerin (NTG), a nitric oxide (NO) donor, has been

208 ediated dilation (FMD), and flow-independent nitroglycerin (NTG)-mediated dilation and vasoreactivity

209 Nitroglycerin (NTG)-triggered central sensitization (CS)

210 nduced by an NO donor diethylamine(DEA)NO or nitroglycerin (NTG).

211 in a canine model of CHF and compared it to nitroglycerin (NTG).

212 and following smooth muscle relaxation with nitroglycerin (NTG).

213 m) was performed before and after sublingual nitroglycerin (NTG).

214 on (FMD) and the dilatation after sublingual nitroglycerin (NTG, 25 microgram) were measured by using

215 atients had significant reduction in angina (nitroglycerin [NTG] use=53.9+/-10.0/wk pre-GTx versus 9.

216 and endothelium-independent vasodilation to nitroglycerin of both axillary arteries were measured.

217 pressors: intraosseous phentolamine, topical nitroglycerin ointment, and intraarterial verapamil and

218 ffects of intrapericardial and intracoronary nitroglycerin on coronary cross-sectional area as assess

219 The effects of intracoronary nitroglycerin on coronary luminal area were used for com

220 Occlusion failed to respond to nitroglycerin or balloon dilation, and stenting was requ

221 Patients who received intravenous nitroglycerin or nesiritide had lower in-hospital mortal

222 No medication, sublingual nitroglycerin or nifedipine was randomly given to each p

223 omenon resulting from continuous exposure to nitroglycerin or other nitrovasodilators.

224 images were similar in patients who received nitroglycerin or placebo.

225 for blood exposed in vitro to 0.1 micromol/L nitroglycerin or the NO donor SNAP, as compared with con

226 nded consideration for use of nitroprusside, nitroglycerin, or nesiritide in addition to diuretics to

227 s (Valsalva maneuver, abdominal compression, nitroglycerin, or vena caval obstruction).

228 ients with or without chest pain relief with nitroglycerin (P > 0.2).

229 ) to the endothelium-independent vasodilator nitroglycerin (p=0.003).

230 in response to acetylcholine (P=0.0006) and nitroglycerin (P=0.04).

231 t further augmented by the administration of nitroglycerin (P=0.648).

232 Application of transdermal nitroglycerin patches or treatment with L-arginine did n

233 025, or 0.1 mg clonidine orally; or combined nitroglycerin plus clonidine.

234 .50+/-4.1%, respectively; P<0.0001), whereas nitroglycerin produced similar vasodilation (14.2+/-5.7%

235 Clonidine but not nitroglycerin reduced aggregate and pain perception aver

236 Nitroglycerin reduced cPP by 10.0 +/- 6.0 mm Hg (p < 0.0

237 -dependent increase in esterase activity and nitroglycerin reductase activity upon addition of coenzy

238 Whereas nitroglycerin reduction occurred in an electrochemical c

239 Nitroglycerin relaxes the stomach without altering perce

240 Nitroglycerin relieved chest pain in 39% of patients (18

241 and -independent agonists (acetylcholine and nitroglycerin, respectively) into the ipsilateral femora

242 ameter in response to reactive hyperemia and nitroglycerin, respectively.

243 holine response (r=0.49, P<0.05) but not the nitroglycerin response (r=0.13, P>0.05).

244 3.2+/-0.8%, P=0.03) but had no effect on the nitroglycerin response.

245 Nitroglycerin responses are not enhanced, but SNP-mediat

246 Infusion of nitroglycerin resulted in a 1.8-fold increase in flow be

247 edistribution images, 58% of those receiving nitroglycerin showed improved reversibility after reinje

248 nt with hydralazine in rabbits not receiving nitroglycerin significantly decreased .O2- production in

249 y records of angina frequency and sublingual nitroglycerin (SL NTG) use.

250 at 10 PM and to note symptoms and sublingual nitroglycerin (SL-NTG) use in a diary.

251 HF-HP patients received nitric oxide donors (nitroglycerin/sodium nitroprusside).

252 OTC had no effect on arterial dilation to nitroglycerin, systemic blood pressure, heart rate, or r

253 uate the effects of intermittent transdermal nitroglycerin (TD-NTG) on the occurrence of ischemia dur

254 Vasodilation to nitroglycerin tended to be lower in the OSAS group (78.6

255 termining nitro compounds of interest (e.g., nitroglycerin) that have poor UV chromophores.

256 tely 7.5 orders of magnitude from 0.05 h for nitroglycerin to 2 x 10(6) h for 2,3,4,5,2',3',5',6'-oct

257 atients more frequently required intravenous nitroglycerin to control the index episode of chest pain

258 Enzymatic pathways converting nitroglycerin to vasoactive compounds have been identifi

259 We used glyceryl trinitrate (nitroglycerin) to trigger premonitory symptoms and migra

260 dmitted for chest pain, relief of pain after nitroglycerin treatment does not predict active coronary

261 e-associated oxidase is activated by chronic nitroglycerin treatment, and the activity of this oxidas

262 creased in wild-type mouse aortas by in vivo nitroglycerin treatment, but this oxidation was lost as

263 With nitroglycerin treatment, similar to SIN-1 treatment, myo

264 ethanol metabolism and decreased efficacy of nitroglycerin treatment.

265 Here, we demonstrate that nitroglycerin triggers constitutive nitric oxide synthas

266 Nitroglycerin undergoes metabolism that generates severa

267 Nitroglycerin usage decreased in active CP but did not c

268 sion, average daily anginal attack count and nitroglycerin usage.

269 es, p = 0.008), as was the weekly sublingual nitroglycerin use (1.7 [95% CI: 1.6 to 1.9] doses vs. 2.

270 ts, ranolazine reduced angina and sublingual nitroglycerin use and was well tolerated.

271 Ranolazine reduced angina attacks and nitroglycerin use by about 1 per week vs placebo (P<.02)

272 bo on weekly angina frequency and sublingual nitroglycerin use in subjects with type 2 diabetes melli

273 s, time to angina, or frequency of angina or nitroglycerin use were noted between groups.

274 Anginal episodes and nitroglycerin use were recorded with daily entry into a

275 significant reductions of angina frequency, nitroglycerin use, and SAQ angina frequency for patients

276 wal due to adverse events, angina frequency, nitroglycerin use, or exercise duration.

277 ia flow-mediated dilation) and -independent (nitroglycerin) vascular responses of the brachial artery

278 The adjusted OR for nesiritide compared with nitroglycerin was 0.94 (95% CI 0.77 to 1.16, p = 0.58).

279 s they developed limiting angina, sublingual nitroglycerin was administered to half the patients, and

280 Intrapericardial nitroglycerin was associated with a mean 31.7% increase

281 In contrast, intracoronary nitroglycerin was associated with a smaller mean increas

282 The response to nitroglycerin was decreased with increasing age (r = -0.

283 troglycerin, and the vascular sensitivity to nitroglycerin was decreased, whereas this tolerance phen

284 Nitroglycerin was detected in soil and water samples fro

285 although the sensitivity of radial artery to nitroglycerin was greater (EC(50)=33+/-7 nmol/L) than th

286 an established contraction (KCl 40 mmol/L); nitroglycerin was most effective in reversing RA contrac

287 Vascular cGMP in response to 0.1 micromol/L nitroglycerin was significantly higher in the radial art

288 reas endothelium-independent vasodilation to nitroglycerin was similar in both groups.

289 reas endothelium-independent vasodilation to nitroglycerin was similar in both groups.

290 atation of the basilar artery in response to nitroglycerin was similar in insulin treated diabetic ra

291 atation of the basilar artery in response to nitroglycerin was similar in non-alcohol-fed and alcohol

292 Maximum relaxation of all vessels to nitroglycerin was similar, although the sensitivity of r

293 tic nitrate ester, glycerol trinitrate (GTN, nitroglycerin), was examined using cultured plant cells

294 x vivo in response to acetylcholine, but not nitroglycerin, was inhibited by transduction of dn-Akt t

295 factor and propensity score-adjusted ORs for nitroglycerin were 0.69 (95% confidence interval [CI] 0.

296 Nifedipine, isosorbide, and nitroglycerin were further evaluated for the ability to

297 uctions in MVO2 in response to diltiazem and nitroglycerin were not altered by inhibiting NO.

298 Dose-response curves to bradykinin and nitroglycerin were obtained from 12 subjects with OSAS a

299 to phenylephrine, acetylcholine, A23187 and nitroglycerin were studied in organ baths.

300 and an endothelium-independent vasodilator, nitroglycerin, were determined.

301 e achieved with intrapericardial delivery of nitroglycerin without systemic hypotension.